Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized dose-ranging study of REG1 versus heparin in acute coronary syndrome
NL-OMON34908Phase 2Withdrawn
- Sponsor
- EPMC Pharma
- Start
- Jun 2010
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of pegnivacogin and Anivamersen in acute coronary syndrome (ACS) and myocardial infarction (MI) (5 arms), sponsored by EPMC Pharma. Primary endpoint: Primary bleeding endpoint. Planned start Jun 2010; status: withdrawn.
02
Drugs
pegnivacoginAnivamersen
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON34908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34908.